The Experts below are selected from a list of 87 Experts worldwide ranked by ideXlab platform
Kiyotaka Fukamachi - One of the best experts on this subject based on the ideXlab platform.
-
early in vivo experience with the pediatric continuous flow total artificial heart
Journal of Heart and Lung Transplantation, 2018Co-Authors: Jamshid H Karimov, David J Horvath, Barry D Kuban, Nicole Byram, Gengo Sunagawa, Shengqiang Gao, Raymond Dessoffy, Kiyotaka FukamachiAbstract:Background Heart transplantation in infants and children is an accepted therapy for end-stage heart failure, but donor organ availability is low and always uncertain. Mechanical circulatory support is another standard option, but there is a lack of intracorporeal devices due to size and functional range. The purpose of this study was to evaluate the in vivo performance of our initial prototype of a pediatric continuous-flow total artificial heart (P-CFTAH), comprising a dual pump with one motor and one Rotating Assembly, supported by a hydrodynamic bearing. Methods In acute studies, the P-CFTAH was implanted in 4 lambs (average weight: 28.7 ± 2.3 kg) via a median sternotomy under cardiopulmonary bypass. Pulmonary and systemic pump performance parameters were recorded. Results The experiments showed good anatomical fit and easy implantation, with an average aortic cross-clamp time of 98 ± 18 minutes. Baseline hemodynamics were stable in all 4 animals (pump speed: 3.4 ± 0.2 krpm; pump flow: 2.1 ± 0.9 liters/min; power: 3.0 ± 0.8 W; arterial pressure: 68 ± 10 mm Hg; left and right atrial pressures: 6 ± 1 mm Hg, for both). Any differences between left and right atrial pressures were maintained within the intended limit of ±5 mm Hg over a wide range of ratios of systemic-to-pulmonary vascular resistance (0.7 to 12), with and without pump-speed modulation. Pump-speed modulation was successfully performed to create arterial pulsation. Conclusion This initial P-CFTAH prototype met the proposed requirements for self-regulation, performance, and pulse modulation.
-
progress on the design and development of the continuous flow total artificial heart
Artificial Organs, 2012Co-Authors: Mariko Kobayashi, David J Horvath, Nicole Mielke, Akira Shiose, Barry D Kuban, Mark S Goodin, Kiyotaka Fukamachi, Leonard A R GoldingAbstract:Cleveland Clinic’s continuous-flow total artificial heart has one motor and one Rotating Assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the Rotating Assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump’s speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ± 10 mm Hg for a wide range of SVR/PVR (systemic/pulmonary vascular resistance) ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development.
Leonard A R Golding - One of the best experts on this subject based on the ideXlab platform.
-
progress on the design and development of the continuous flow total artificial heart
Artificial Organs, 2012Co-Authors: Mariko Kobayashi, David J Horvath, Nicole Mielke, Akira Shiose, Barry D Kuban, Mark S Goodin, Kiyotaka Fukamachi, Leonard A R GoldingAbstract:Cleveland Clinic’s continuous-flow total artificial heart has one motor and one Rotating Assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the Rotating Assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump’s speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ± 10 mm Hg for a wide range of SVR/PVR (systemic/pulmonary vascular resistance) ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development.
Barry D Kuban - One of the best experts on this subject based on the ideXlab platform.
-
early in vivo experience with the pediatric continuous flow total artificial heart
Journal of Heart and Lung Transplantation, 2018Co-Authors: Jamshid H Karimov, David J Horvath, Barry D Kuban, Nicole Byram, Gengo Sunagawa, Shengqiang Gao, Raymond Dessoffy, Kiyotaka FukamachiAbstract:Background Heart transplantation in infants and children is an accepted therapy for end-stage heart failure, but donor organ availability is low and always uncertain. Mechanical circulatory support is another standard option, but there is a lack of intracorporeal devices due to size and functional range. The purpose of this study was to evaluate the in vivo performance of our initial prototype of a pediatric continuous-flow total artificial heart (P-CFTAH), comprising a dual pump with one motor and one Rotating Assembly, supported by a hydrodynamic bearing. Methods In acute studies, the P-CFTAH was implanted in 4 lambs (average weight: 28.7 ± 2.3 kg) via a median sternotomy under cardiopulmonary bypass. Pulmonary and systemic pump performance parameters were recorded. Results The experiments showed good anatomical fit and easy implantation, with an average aortic cross-clamp time of 98 ± 18 minutes. Baseline hemodynamics were stable in all 4 animals (pump speed: 3.4 ± 0.2 krpm; pump flow: 2.1 ± 0.9 liters/min; power: 3.0 ± 0.8 W; arterial pressure: 68 ± 10 mm Hg; left and right atrial pressures: 6 ± 1 mm Hg, for both). Any differences between left and right atrial pressures were maintained within the intended limit of ±5 mm Hg over a wide range of ratios of systemic-to-pulmonary vascular resistance (0.7 to 12), with and without pump-speed modulation. Pump-speed modulation was successfully performed to create arterial pulsation. Conclusion This initial P-CFTAH prototype met the proposed requirements for self-regulation, performance, and pulse modulation.
-
progress on the design and development of the continuous flow total artificial heart
Artificial Organs, 2012Co-Authors: Mariko Kobayashi, David J Horvath, Nicole Mielke, Akira Shiose, Barry D Kuban, Mark S Goodin, Kiyotaka Fukamachi, Leonard A R GoldingAbstract:Cleveland Clinic’s continuous-flow total artificial heart has one motor and one Rotating Assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the Rotating Assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump’s speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ± 10 mm Hg for a wide range of SVR/PVR (systemic/pulmonary vascular resistance) ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development.
David J Horvath - One of the best experts on this subject based on the ideXlab platform.
-
early in vivo experience with the pediatric continuous flow total artificial heart
Journal of Heart and Lung Transplantation, 2018Co-Authors: Jamshid H Karimov, David J Horvath, Barry D Kuban, Nicole Byram, Gengo Sunagawa, Shengqiang Gao, Raymond Dessoffy, Kiyotaka FukamachiAbstract:Background Heart transplantation in infants and children is an accepted therapy for end-stage heart failure, but donor organ availability is low and always uncertain. Mechanical circulatory support is another standard option, but there is a lack of intracorporeal devices due to size and functional range. The purpose of this study was to evaluate the in vivo performance of our initial prototype of a pediatric continuous-flow total artificial heart (P-CFTAH), comprising a dual pump with one motor and one Rotating Assembly, supported by a hydrodynamic bearing. Methods In acute studies, the P-CFTAH was implanted in 4 lambs (average weight: 28.7 ± 2.3 kg) via a median sternotomy under cardiopulmonary bypass. Pulmonary and systemic pump performance parameters were recorded. Results The experiments showed good anatomical fit and easy implantation, with an average aortic cross-clamp time of 98 ± 18 minutes. Baseline hemodynamics were stable in all 4 animals (pump speed: 3.4 ± 0.2 krpm; pump flow: 2.1 ± 0.9 liters/min; power: 3.0 ± 0.8 W; arterial pressure: 68 ± 10 mm Hg; left and right atrial pressures: 6 ± 1 mm Hg, for both). Any differences between left and right atrial pressures were maintained within the intended limit of ±5 mm Hg over a wide range of ratios of systemic-to-pulmonary vascular resistance (0.7 to 12), with and without pump-speed modulation. Pump-speed modulation was successfully performed to create arterial pulsation. Conclusion This initial P-CFTAH prototype met the proposed requirements for self-regulation, performance, and pulse modulation.
-
progress on the design and development of the continuous flow total artificial heart
Artificial Organs, 2012Co-Authors: Mariko Kobayashi, David J Horvath, Nicole Mielke, Akira Shiose, Barry D Kuban, Mark S Goodin, Kiyotaka Fukamachi, Leonard A R GoldingAbstract:Cleveland Clinic’s continuous-flow total artificial heart has one motor and one Rotating Assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the Rotating Assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump’s speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ± 10 mm Hg for a wide range of SVR/PVR (systemic/pulmonary vascular resistance) ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development.
Mariko Kobayashi - One of the best experts on this subject based on the ideXlab platform.
-
progress on the design and development of the continuous flow total artificial heart
Artificial Organs, 2012Co-Authors: Mariko Kobayashi, David J Horvath, Nicole Mielke, Akira Shiose, Barry D Kuban, Mark S Goodin, Kiyotaka Fukamachi, Leonard A R GoldingAbstract:Cleveland Clinic’s continuous-flow total artificial heart has one motor and one Rotating Assembly supported by a hydrodynamic bearing. The right hydraulic output is self regulated by passive axial movement of the Rotating Assembly to balance itself with the left output. The purpose of this article is to present progress in four areas of development: the automatic speed control system, self-regulation to balance right/left inlet pressures and flows, hemolysis testing using calf blood, and coupled electromagnetics (EMAG) and computational fluid dynamics (CFD) analysis. The relationships between functions of motor power and speed, systemic flow, and systemic vascular resistance (SVR) were used for the sensorless speed control algorithm and demonstrated close correlations. Based on those empirical relationships, systemic flow and SVR were calculated in the system module and showed good correlation with measured pump flow and SVR. The automatic system adjusted the pump’s speed to obtain the target flow in response to the calculated SVR. Atrial pressure difference (left minus right atrial pressure) was maintained within ± 10 mm Hg for a wide range of SVR/PVR (systemic/pulmonary vascular resistance) ratios, demonstrating a wide margin of self-regulation under fixed-speed mode and 25% sinusoidally modulated speed mode. Hemolysis test results indicated acceptable values (normalized index of hemolysis <.01 mg/dL). The coupled EMAG/CFD model was validated for use in further device development.
